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Lymph node stromal cells (LNSCs) have newly been promoted to the rank of new 
modulators of T cell responses. The different non-hematopoietic cell subsets in lymph 
node (LN) were considered for years as a simple scaffold, forming routes and proper 
environment for antigen (Ag)-lymphocyte encountering. Deeper characterization of 
those cells has recently clearly shown their impact on both dendritic cell and T cell 
functions. In particular, lymphatic endothelial cells (LECs) control lymphocyte trafficking 
and homeostasis in LNs and limit adaptive immune responses. Therefore, the new role of 
LECs in shaping immune responses has drawn the attention of immunologists. Striking 
is the discovery that LECs, among other LNSCs, ectopically express a large range 
of peripheral tissue-restricted Ags (PTAs), and further present PTA-derived peptides 
through major histocompatibility class I molecules to induce self-reactive CD8+ T cell 
deletional tolerance. In addition, both steady-state and tumor-associated LECs were 
described to be capable of exogenous Ag cross-presentation. Whether LECs can 
similarly impact CD4+ T cell responses through major histocompatibility class II restricted 
Ag presentation is still a matter of debate. Here, we review and discuss our current 
knowledge on the contribution of Ag-presenting LECs as regulators of peripheral T cell 
responses in different immunological contexts, including autoimmunity and cancer.
Keywords: lymphatic endothelial cells, peripheral tissue antigens, antigen presentation, immunomodulation, 
tolerance
iNTRODUCTiON
The lymphatic system comprises a network of vessels together with lymphoid tissues all over the body 
that drain the extracellular compartment from most of the tissues. It transports lymph fluid, which 
is composed of immune cells and proteins drained from interstitial tissues, and helps to dispose of 
toxins and other unwanted components from the body. Lymphocytes follow the lymphatic system to 
migrate to infection sites, which supports and facilitates immune responses against potential harms. 
Frequently underestimated by scientists, the importance of lymphatics in controlling the immune 
system beyond the regulation of leukocyte trafficking has reached a new level with recent discoveries.
The initial observations of the lymphatic system date back to the Ancient Greece, referred to 
as “white blood.” However, it was in the seventeenth century that Asellius formally discovered the 
lymphatic vessels or, what he called, the “milky veins” from mesenteries in dogs (1). Several diseases 
have been described to result from failures in the lymphatic system, some of them having life-
threatening consequences, such as lymphedema (2). Even more strikingly, the role of lymphatics in 
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tumor spreading is known since the eighteenth century. Despite 
the ancient knowledge in the lymphatic system organization, 
our understanding in its multiple functions has rapidly evolved 
thanks to the unveiling of lymphatic endothelial cell (LEC) 
specific markers, such as the surface protein Lyve-1 or the tran-
scription factor Prox-1, which are lacking in other endothelial 
cells. Several studies have subsequently demonstrated that LECs 
impact immune responses in many ways, including the modula-
tion of immune cell migration and encounter, effector functions, 
and survival. In this review, we discuss our current understand-
ing of the imunoregulatory properties of LECs. We specifically 
discuss the ability of LECs to directly impact T cell responses by 
presenting endogenous or exogenous antigens (Ags) to T cells in 
lymph nodes (LNs), and therefore to shape Ag-specific peripheral 
T cell responses in the context of autoimmunity and cancers.
ORiGiN AND TYPeS OF LYMPHATiCS
LeC Development
Nowadays, it is well accepted and documented that, during 
embryogenesis, LECs differentiate from specialized angioblasts 
in the developing veins (3, 4). Nevertheless, this has been con-
troversial for long until just few decades ago due to, in particular, 
the lack of knowledge on lymphatic-specific markers. Two dif-
ferent hypotheses raised in early twentieth century debated the 
possible origin of the lymphatic system. On one hand, studies on 
embryonic cats suggested that primary lymph sacs arised from 
mesenchymal progenitors (5). On the other hand, intravenous 
injection of ink in pig embryos revealed that lymph sacs devel-
oped from budding of embryonic veins (6, 7). The identification 
of the vascular endothelial growth factor receptor-3 (VEGFR-3) 
(8) reinforced the latter hypothesis of a common origin for both 
lymphatic and blood endothelial cells (BECs). In adulthood, 
VEGFR-3 expression is restricted to LECs (8, 9). However, it 
is also expressed by angioblasts and developing veins during 
embryonic development (8, 10, 11). Impaired development of 
both lymphatic and blood endothelium in VEGFR-3-deficient 
mice suggested a common progenitor for LECs and BECs (11). 
Further ratification of VEGFR-3 requirement for lymphatic 
development was provided by studies modulating the expres-
sion of its main ligand, the vascular endothelial growth factor 
C (VEGF-C). Overexpression of VEGF-C induced lymphatic 
sprouting and lymphangiogenesis (12–14).
The identification of the homeobox gene Prox-1 in 1993 led 
few years later to the final confirmation of the theory propos-
ing the venous origin of lymphatics. Deletion of Prox-1 in mice 
results in the absence of early lymphatic endothelial differentia-
tion and, as a consequence, Prox-1 knockout mice totally lack the 
lymphatic system (10, 15). Prox-1 expression in particular cells 
of the embryonic veins at E9.5 starts the lymphatic polarization 
and imprints the LEC signature (10, 15, 16). Transcriptome 
studies showed high proximity in LECs and BECs gene expres-
sion profiles. However, Prox-1 acts as the specific regulator 
of genes that are inversely regulated in a type-specific manner 
(17, 18). Indeed, potentially all venous endothelial cells may 
give rise to blood or lymphatic endothelium as demonstrated 
by Prox-1-induced reprograming when overexpressed in BECs 
(16). After development, functional Prox-1 is required to main-
tain the lymphatic phenotype (19). The molecular mechanisms 
of Prox-1-driven lymphatic differentiation have been reviewed 
recently (4). In addition, recent studies in zebrafish validated 
the molecular mechanisms governing lymphatic development, 
further demonstrating that the vast majority of cells contributing 
to LECs in thoracic ducts of zebrafish raised from primitive veins 
(3, 20). Later in development, however, the origin of organ-
specific lymphatic vasculature might be slightly different. Using 
cell-fate mapping technologies, a recent publication suggested a 
combination of venous- and non-venous-derived LECs in the 
developing cardiac lymphatics (21). This spatiotemporal discrep-
ancy may explain the difficulties experienced in obtaining a fully 
convincing explanation in the origin of LECs.
The specification of LECs during development entails struc-
tural and functional differences between blood and lymphatic 
systems. In sharp contrast to the circular and closed blood 
vasculature, lymphatic circulation appears as a linear- and 
blind-ended circuit. Capillaries of the lymphatic system drain 
interstitial fluids from peripheral organs and tissues thanks to 
the particular organization of LECs in the terminal lymphatics. 
The uptake of interstitial fluid, macromolecules, and cells is pos-
sible due to the highly permeable thin-walled capillary vessels 
composed of a single layer of LECs, which are not covered by 
pericytes or smooth muscle cells and have little or no basement 
membrane (22). Lymphatic capillaries exhibit discontinuous or 
“button-like” junctions where the interjunctional gaps act as sites 
of leukocyte entry into the vessels (23, 24). Terminal lymphatic 
capillaries are linked to the surrounding extracellular matrix by 
anchoring filaments that sense changes in interstitial pressures 
during inflammation. This results in vessel lumen and junction 
aperture, therefore facilitating the uptake of tissue-derived fluids. 
Deeper, lymphatics change from a drainage-prone phenotype to 
a collector vessel morphology specialized in lymph transport. 
Collecting lymphatics are surrounded by pericytes and smooth 
muscle cells and possess a basement membrane, displaying con-
tinuous “zipper-like” junctions. The presence of valves (22, 23) 
ensures the lymph circulation while preventing retrograde flow.
Main LeC Types
Lymphatic vessels are present in almost all the vascularized 
organs, with the exception of the bone marrow. LEC immune 
modulatory properties represent a growing research area. LN 
LECs being the most characterized subset and representing the 
objective of this review is not discussed in this section.
However, lessons taken from studies performed during the 
last decade clearly establish different functions and possible roles 
for LECs from different anatomic locations. Deeper and careful 
future analyses will identify specific immunoregulatory features 
of distinct LEC populations.
For decades, lymphatic drainage was suggested to be involved 
in local immune responses (25). Dendritic cells (DCs) draw all 
the attention in initiating and eliciting tolerance or activation 
of the immune system. However, the role of lymph drainage in 
modulating adaptive immunity and tolerance remained largely 
unexplored. K14-VEGFR-3-Ig mice express soluble VEGFR-3-Ig 
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via the keratin 14 promoter, resulting in a lack of lymphatic 
growth, which is restricted to the skin, and in a drop in fluid 
clearance (26). In these mice, local lymphatic drainage appeared 
to be critical for humoral immunity and acquired tolerance, while 
T cell responses remained delayed but mostly unaffected. There 
is no doubt that additional mechanisms and functions of dermal 
LECs will be discovered in the future.
LSECs could be seen as LEC counterparts in the liver. First 
described in 1970 (27), LSECs possess a high ability to filter fluids, 
solutes, and particles from hepatic circulation, occupy a large 
surface area exposed to blood that carries external food and com-
mensal bacterial Ag, and are known to cross-present exogenous 
Ag to T cells (28).
A traditional dogma states the immune privilege and lack 
of lymphatic system in the central nervous system (CNS). This 
idea has persisted despite the notion of immune surveillance of 
T cells in the brain (29). A recent and elegant study identified 
for the first time the lymphatic vasculature in a specific area of 
the meninges lining the dural sinuses (30). The vessels express 
LEC-specific markers such as Lyve-1, Prox-1, or Podoplanin and 
drain the cerebrospinal fluid to deep cervical LNs. These findings 
provide new insights in the establishment and progression of 
some neurological diseases involving immune cell contribution, 
such as multiple sclerosis or Alzheimer’s. Moreover, CNS-resident 
stromal fibroblastic and endothelial cells were shown to guide 
antiviral CD8+ T cell responses in a model of virus-induced neu-
roinflammation (31). The production of CCR7 ligands CCL19 
and CCL21 by CNS stromal cells was found critical for the induc-
tion of viral-specific T cell recruitment and the support of local T 
cell reactivation. Whether newly discovered CNS lymphatics (30) 
similarly contribute to neuroinflammatory immunopathologies 
remains to be determined.
Lymphatic development in the tumor microenvironment, 
known as tumor lymphangiogenesis, has been extensively stud-
ied. The participation of tumor lymphatics in the spread of the 
disease, or metastasis, has been studied for many years. In fact, 
most human melanomas and carcinomas metastasize through the 
lymphatic system (32). The presence of tumor-associated LECs 
correlates with bad clinical outcome in several types of cancer 
(33) and therapies aiming the blockade of tumor lymphangiogen-
esis are being considered for treatment of such malignancies (34). 
Growing evidence highlight the impact of tumor-associated LECs 
in dampening antitumor immunity. How interactions between 
lymphatics and T cells in the context of tumor development will 
further alter T cell responses is discussed below.
Ag PReSeNTATiON iNDePeNDeNT 
iMPACT OF LeCs ON PeRiPHeRAL  
T CeLL ReSPONSeS
Hallmarks of T cell immunity include the generation of pathogen-
specific effector responses to confer protection against a large 
range of invaders, without causing unwanted self-tissue damage. 
Naïve T cells constantly scan for their cognate Ag. However, given 
the extremely low frequency of T cells being specific for a particu-
lar peptide–major histocompatibility (MHC) complex (35, 36), 
this challenging task is strictly located into highly organized 
secondary lymphoid organs (SLOs), such as LNs, Peyer’s patches 
(PPs), and the spleen. These SLOs contain both tissue-derived and 
blood-borne Ags, therefore facilitating naïve T cell-Ag encounter, 
and subsequent T cell activation and differentiation into T cell 
effectors. This part summarizes the different pathways by which 
LECs will impact T cell outcome inside and after exiting LNs.
Ag Delivery to LNs
As described before, LNs are connected to lymphatics, which 
drain peripheral tissue-derived fluids. By connecting tissues to 
draining LNs, LECs facilitate the passive entry of tissue-derived 
Ags that can thereby be captured, processed, and presented by 
resident DCs to T cells entering LNs through high endothelial 
venules (37, 38). Soluble Ags are immediately sampled by LN 
DCs, whereas particles carrying Ags, such as exosomes, apop-
totic bodies or microvesicles, which have not been captured by 
subcapsular sinus macrophages, flow to LN medullary sinuses 
where they can be sampled by DCs (39). LECs also support the 
active migration of tissue-resident DCs into LNs. DC migration 
from tissues to draining LNs via lymphatic vessels is an important 
way to present Ags and activate naïve T cells. DCs enter affer-
ent lymphatics through preformed portals (40), independent 
of integrin-mediated adhesion (41). However, LECs upregulate 
adhesion molecules upon inflammation, further favoring DC 
access to lymphatic vessels (42). In addition, expression of CLEC2 
(a C-type lectin receptor) by DCs promotes their migration to 
LNs via lymphatics through interaction with its ligand gp38 
(Podoplanin), which is expressed by both LECs and fibroblastic 
reticular cells (FRCs) (43).
Modulation of DC Functions
Tissue-resident DCs having acquired peripheral Ags subse-
quently migrate through afferent lymphatics into LNs in a 
CCR7-dependent manner. However, the lymphatic system does 
not only support DC migration from tissues to LNs. Indeed, 
close interactions between migrating DCs and LECs induce 
phenotypic and functional changes in DCs. First, contacts 
between TNF-α-stimulated LECs and DCs lead to decreased 
expression of costimulatory molecules by DCs in  vitro, thus 
impairing DC ability to induce T cell proliferation (44). LEC-
mediated regulation of DC functions is dependent on interac-
tions between CD11b (Mac-1) on DCs and ICAM-1 on LECs 
(44). Interestingly, LECs are able to inhibit the function of 
LPS-activated DCs, suggesting once again a regulatory role for 
LECs in the resolution phase of inflammation. A recent report 
demonstrated that LECs function as reservoirs of peripheral 
tissue-restricted Ags (PTAs), which are subsequently acquired 
and presented by DCs to induce T cell anergy, therefore contrib-
uting to peripheral CD4+ T cell tolerance (45).
T Cell Homeostasis
While T cell migration inside LNs is mainly driven by CCL19 and 
CCL21 produced by FRCs (46), naive and memory T lymphocyte 
maintenance in SLOs is highly dependent on IL-7. Together with 
FRCs (47), LECs represent an important source of IL-7 in vivo, 
regulating lymphocyte homeostasis and access to SLOs. IL-7-GFP 
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knock-in mice exhibit moderate GFP expression in LN-FRCs, 
whereas high levels were detected in both LN LECs and tissue 
LECs (48, 49). Similarly, LECs were shown to be the major source 
of IL-7 in both human and murine LNs (50). Furthermore, 
LECs not only produce IL-7 but also express the IL-7 receptor 
chains IL-7Rα and CD132, suggesting a possible role for IL-7 as 
an autocrine mediator of lymphatic drainage. IL-7-stimulated 
LECs induced lymphangiogenesis in the cornea of mice in vitro, 
whereas in IL-7Rα−/− mice, lymphatic drainage was compromised 
(51). In addition, IL-7 upregulation by both FRCs and LECs is 
essential for LN reconstruction and remodeling following viral 
infection or avascular transplantation (50). This suggests that 
IL-7 production in LN after resolution of an infection could 
be involved in memory T cell homeostasis. Accordingly, IL-7 
promotes the development, the proliferation, and the survival of 
memory CD8+ T cells (52, 53).
T Cell egress from LNs
T cell egress from LNs is dependent on their expression of the 
sphingosine-1-phosphate (S1P) receptor (S1PR1). Using mice 
lacking S1P selectively in LECs while maintaining normal blood 
S1P, Cyster and collaborators have shown that LECs are an 
in vivo source of S1P in LNs, allowing T cell egress from LNs 
and PPs (54). S1PR1 expression is downregulated by blood 
circulating lymphocytes, and upregulated in LNs. Interactions 
between S1P-producing LECs and S1P1R-expressing T cells 
promote LN egress by overcoming retention signals mediated 
by CCR7 (55, 56). Although steady-state LECs express low levels 
of S1P, its production is upregulated in medullary sinus LECs 
upon PAMP/DAMP-mediated inflammation, suggesting that 
high S1P-expressing LECs can promote effector T cell egress 
from LNs in pathogenic situations. In contrast, in non-infectious 
sterile inflammatory contexts, low S1P-producing LECs would 
rather dampen T cell effector functions by favoring T cell reten-
tion in LNs.
T Cell Migration in Tumor-Associated 
Lymphatics
Increasing evidence suggest that tumor-associated lymphatics 
not only simply function as tumor cell transporters but also 
play additional important roles impacting tumor development. 
Accordingly, not only metastatic but also primary tumor progres-
sion can be affected by modulating tumor-associated lymphatic 
expansion. In the context of solid tumors, lymph flow from tumors 
is elevated, driving intense interstitial flow in the tumor stroma 
and increasing lymphatic drainage from the tumor to the drain-
ing LN (57). Combined with a suppressive cytokine environment, 
it is therefore possible that increased tumor Ags drainage could 
promote tumor-specific T cell dysfunction, including anergy and 
apoptosis. In addition, the lymph supports cells migrating from 
tissues, in particular CCR7+ DCs, a phenomenon shown to be 
critical for initiating antitumor immune responses (58).
Tumor infiltration by T cells is one of the key steps in antitumor 
immunity. While cytotoxic T lymphocyte infiltration correlates 
with good prognosis, accumulation of T regulatory cells (Treg) 
or naïve T cells is detrimental for the clinical outcome (59, 60). 
Likewise, expression of CCL21 in the tumor promotes immune 
escape and tumor progression (61), which may be explained, at 
least in part, by the enhancement of naïve T cell recruitment. 
Although T cell receptor (TCR)-transgenic tumor-infiltrating 
naïve T cells may be activated in  situ (62), it is unlikely, given 
the immunosuppressive tumor-related environment, that this 
will lead to fully competent effector T cell differentiation. In this 
regard, it is still to be demonstrated whether CCL21-producing 
LECs contribute to this effect. How LECs contribute to the overall 
tolerogenic properties of the tumor microenvironment is still an 
open question.
We have demonstrated that the lymphangiogenic growth factor 
VEGF-C produced in the tumor promoted immunological toler-
ance in murine melanoma (63). VEGF-C protected tumors against 
preexisting antitumor immunity and promoted local deletion of 
tumor-specific CD8+ T cells (63, 64). Our findings introduce a 
new role for lymphatics in promoting tumor development and 
suggest that lymphatic endothelium in the local microenviron-
ment may be a novel target for immunomodulation. Supporting 
those hypotheses there is a recent publication demonstrating 
that following exposure to tumor-derived factors, FRCs of the 
tumor-draining LNs adapt on multiple levels to exhibit features 
associated with immunosuppression, such as decreased produc-
tion of IL-7 and CCL19/21 (65). Whether a similar profound 
reprograming occurs to LECs in tumor-draining LNs remains to 
be determined.
Ag PReSeNTATiON-DePeNDeNT iMPACT 
OF LeCs ON PeRiPHeRAL T CeLL 
ReSPONSeS
In addition to their ability to modulate T cell responses by 
impacting immune cell migration, interactions, and homeostasis, 
LECs can also function as Ag-presenting cells through several 
mechanisms and directly influence peripheral T cell outcome.
Presentation of endogenously expressed 
PTAs to T Cells by LeCs
In order to prevent autoimmunity, thymocytes go through a pro-
cess of negative selection, part of the so-called central tolerance, 
allowing the deletion of autoreactive T cell clones before they exit 
from the thymus to enter into the periphery [reviewed in Ref. (66, 
67)]. In the thymus, medullary thymic epithelial cells (mTECs) 
promiscuously express PTAs, Ag that are normally expressed in 
the periphery (68, 69). The expression of a vast majority of PTAs 
in mTECs is regulated by transcription factors (70), including 
the autoimmune regulator (Aire), mutations in Aire leading to 
severe autoimmune disorders (71, 72). PTAs can be either directly 
presented by mTECs to the thymocytes, acquired from mTECs 
by thymus-resident DCs or acquired in tissues by migrating DCs 
or plasmacytoid DCs (pDCs), and cross-presented to the thymo-
cytes (73–76) (Figure 1A). Thymocytes expressing a TCR with 
a too high affinity for self-Ag/MHC complexes undergo clonal 
deletion (73–75). A fraction of the CD4+ thymocytes having a 
TCR with a high affinity differentiates into thymus-derived Tregs 
(tTregs), previously called natural Tregs (nTregs), and expresses 
FiGURe 1 | Maintenance of T cell tolerance. (A) Schematic view of thymic central tolerance, reviewed in Ref. (67). After positive selection (not depicted), simple 
positive (SP) thymocytes undergo a process of negative selection. Thymus-resident conventional dendritic cells (cDCs) and peripheral tissue-restricted antigens 
(Ags) (PTA) (green)-expressing medullary thymic epithelial cells, as well as peripheral plasmacytoid DCs (pDCs) and cDCs, that have acquired Ag (yellow) in the 
periphery and migrate to the thymus, present self-peptide major histocompatibility complex (MHC) complexes to SP thymocytes. Thymocytes expressing a T cell 
receptor (TCR) with high affinity for self (dark colors) are clonally deleted. SP expressing a TCR with intermediate affinity differentiate into thymus-derived T regulatory 
cell (tTreg) (medium colors). Low-affinity TCR-expressing SP (light colors) exit from the thymus and enter the periphery, however comprising some self-reactive  
T cells (dark colors) that escaped central tolerance. (B) Peripheral T cell tolerance in the lymph nodes (LNs). References related to lymph node stromal cell 
contributions are indicated (numbers). Self-Ag-specific T cell tolerance is further maintained in the periphery in LNs. cDCs and pDCs acquire Ag from peripheral 
tissues (yellow) and migrate to LNs to present Ag to autoreactive T cells. cDCs also acquire Ag expressed by lymphatic endothelial cells (LECs). LECs, fibroblastic 
reticular cells, and blood endothelial cells present endogenously expressed PTAs (pink), as well as peptide–MHC-II complexes acquired from cDCs, therefore 
contributing to peripheral T cell tolerance via distinct mechanisms. Extrathymic autoimmune regulator (Aire)-expressing cells (eTACs) present endogenously 
expressed PTAs. The outcome of Ag presentation by each cell subtype is depicted in the figure. Cell migration and Ag transfer are represented by dotted and 
dashed arrows, respectively. exo Ags, exogenous antigens; migr. cDC, migratory cDC; pTreg, peripherally induced Treg; thym. cDC, thymus-resident cDC.
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the transcription factor Foxp3 (77). A population of CD8+ Foxp3+ 
tTregs has also been described (78–81). However, some autore-
active—non-Treg—T cells do escape thymic central tolerance 
mechanisms and reach the periphery (82, 83), as a result from 
either an absence of specific self-Ag presentation in the thymus, 
or a lack of deletion due to a TCR exhibiting an affinity for self-
Ag/MHC complexes below the negative selection threshold (84) 
(Figure 1A).
Therefore, additional mechanisms, called peripheral tolerance 
mechanisms, have evolved to maintain T cell tolerance apart 
from the thymus [reviewed in Ref. (66, 85)]. Cross-tolerance 
induction by peripheral DCs has been extensively studied and 
reviewed over the past two decades (86); immature DCs acquire 
Ag through the phagocytosis of apoptotic cells in peripheral tis-
sues to present them to T cells in SLOs (87–89). In the absence of 
costimulatory signals, Ag presentation leads to CD4+ and CD8+ 
T cell clonal deletion (physical elimination) or anergy (functional 
inactivation) and/or to the induction of peripherally induced 
Tregs (pTregs), previously called induced Tregs (iTregs) in the 
presence of anti-inflammatory factors (77, 90–92). Both resident 
and migratory DCs, including pDCs, contribute to this process 
in the LNs (93–96) (Figure 1B). Nevertheless, emerging evidence 
demonstrates that peripheral tolerance does not exclusively rely 
on DCs. Lymph node stromal cells (LNSCs), and in particular 
LECs, also play an important role in the maintenance of periph-
eral tolerance (Figure 1B).
PTA-specific expression by LeCs
The discovery of the ectopic PTA expression by mTECs in the 
thymus was the first example that cells of non-hematopoietic 
origin present endogenously expressed self-Ag to T cells (68, 69). 
Using GFAP-HA or iFABP-tOVA transgenic mouse models, in 
which hemagglutinin (HA) or a truncated form of ovalbumin 
(tOVA) are expressed as self-Ag in enteric glial cells (EGCs) or 
mature intestinal epithelial cells (IECs), respectively, it was shown 
few years ago that the EGC-associated HA or IEC-associated 
tOVA proteins were unexpectedly expressed not only by EGCs or 
IECs but also by CD45-negative stromal cells, in all LNs and not 
exclusively in mesenteric LNs. Those LNSCs were able to process 
endogenously expressed self-proteins into antigenic peptides 
to directly present these Ag to CD8+ T cells in SLOs, making 
them functionally similar to mTECs in the thymus (97–100). 
Moreover, it was shown in non-transgenic mouse models that 
LNSCs naturally express PTAs and directly present them to 
CD8+ T cells. Among other examples, LNSCs ectopically express 
tyrosinase (tyr), while its expression is normally confined to 
melanocytes (101). It was later shown that LECs are the only cells 
ectopically expressing this Ag in the LN (102, 103). Indeed, using 
CD31 and gp38 (Podoplanin) as markers to distinguish the LNSC 
subtypes, it was observed that each subtype expresses a distinct 
set of PTAs, with some PTAs exclusively expressed in one specific 
LNSC subset and some others redundantly expressed (102, 103) 
(Figure 1B). This suggests a non-redundant role for the different 
LNSC subtypes in the tolerization of various self-specific T cells. 
In addition, the expression of PTAs by LECs is subanatomically 
compartmentalized, with a high expression of PTAs observed 
only in LN medullary sinus LECs (104).
In mTECs, the expression of most, but not all, PTAs is 
regulated by Aire (70, 71). In the LN, a rare bone marrow-
derived population was described to express Aire and was 
called extrathymic Aire-expressing cells (eTACs). Consequently, 
eTACs express various PTAs in an Aire-dependent manner, and 
present them through major histocompatibility complex class I 
(MHC-I) and MHC-II molecules to induce CD8+ T cell deletion 
(105), and CD4+ T cell anergy (106), respectively (Figure 1B). 
On the contrary, PTAs expressed by non-hematopoietic LNSCs, 
including LECs, are not dependent on Aire (103). The regulation 
of the expression of the pancreatic self-Ag Ppy by LECs in 
pancreatic LNs depends on the transcriptional regulator Deaf1, 
which, together with Aire, belongs to the SAND gene family 
(107, 108). Interestingly, variant isoforms of Deaf1 in mice and 
human display an impaired Ppy expression, and were linked 
to autoimmune type I diabetes (107). The fact that LNSCs 
do not express Aire may explain the low overlapping PTA 
expression in mTECs and LNSCs (109), therefore suggesting 
a complementary contribution of mTECs and LNSCs in T cell 
tolerance induction and maintenance. Future investigations will 
identify other transcription factors, selectively or commonly 
expressed by LNSC subsets, which promote different PTA 
expression.
PTA Presentation by LeCs to T Cells
LNSCs not only endogenously express PTAs but also the direct 
presentation of PTA-derived peptides in the context of MHC-I 
molecules to CD8+ T cells leads to their clonal deletion and 
subsequent tolerance induction (97, 98, 101) (Figure  1B). In 
the GFAP-HA or iFABP-tOVA models mentioned above, the 
lack of presentation of HA or tOVA by enteric stromal cells to 
HA- or tOVA-specific CD8+ T cells was associated with enteric 
autoimmunity. Among other LNSC subsets, LECs are involved 
in this CD8+ T cell deletional tolerance and are necessary and 
sufficient for the induction of peripheral tolerance to some self-
Ag, like Tyr, an autoantigen associated with autoimmune vitiligo 
(102, 103, 107). These studies show a crucial role for LECs in the 
maintenance of peripheral tolerance.
Nevertheless, the ability of LNSCs, and in particular LECs, to 
directly present endogenously expressed PTAs in the context of 
MHC-II molecules to CD4+ T cells is still a matter of debate, as 
well as the subsequent impact on CD4+ T cell outcome. We have 
previously shown that the endogenous expression of MHC-II 
molecules is regulated in LECs, BECs, and FRCs by the promoter 
IV (pIV) of the master regulator CIITA (110). One study has 
however demonstrated that the adoptive transfer of HA-specific 
TCR transgenic CD4+ T cells (6.5) in GFAP-HA transgenic 
mice, in which HA is expressed as an autoantigen by EGCs, 
did not dampen lethal enteric autoimmunity (98). However, as 
mentioned by the authors, the absence of direct presentation of 
HA peptide by LNSCs to HA-specific CD4+ T cells in their model 
does not rule out a possible upregulation of MHC-II molecules 
in LNSCs and a direct presentation under pro-inflammatory 
conditions (98). Indeed, several studies that will be discussed 
later in this review have suggested that LNSCs, among which 
LECs, upregulate MHC-II molecules at their surface upon 
inflammation (110, 111).
7Humbert et al. Role of LECs in Peripheral T Cell Responses
Frontiers in Immunology | www.frontiersin.org January 2017 | Volume 7 | Article 684
For their part, Engelhard and colleagues claim that LECs are 
unable to present endogenously expressed PTAs (β-galactosidase, 
membrane-bound HA or I-Eα in their models) to CD4+ T cells, 
not related to Ag localization but due to a lack of H2-M expres-
sion in LECs, which would prevent the loading of peptides onto 
MHC-II molecules (45). However, this study was carried out in 
the steady state, whereas LECs, BECs, and FRCs, that express 
IFN-γ inducible-CIITA pIV, might require IFN-γ to upregulate 
H-2M molecules, as they do for MHC-II expression, these two 
genes being co-regulated by CIITA (112). Moreover, Mebius and 
colleagues observed the presence of mRNA transcripts for H2-M 
in LECs, among other MHC-II-related molecules (113).
Mebius and colleagues identified that in transgenic mice 
expressing OVA under the control of the keratin 14 promoter 
(K14mOVA mice), OVA was unexpectedly expressed in LECs. In 
addition, OVA+ LEC were able to present OVA peptides through 
MHC-II to OTII cells in vitro, leading to an increased Foxp3+ 
OT-II cells Treg homeostasis (113). Using LN transplantation 
experiments, the authors further suggested that the presentation 
of endogenously expressed self-Ag by LNSCs, and especially by 
LECs, contribute in  vivo to the maintenance of Foxp3+ CD4+ 
Tregs in the periphery (Figure  1B) (113). Finally, lentiviral 
vectors allowing the selective transduction of MHC-II+ non-
hematopoietic cells with MHC-II- and MHC-I-restricted HY 
male-derived epitopes induced T cell hyporesponsiveness/
anergy of HY-specific CD4+ and CD8+ T cells in female mice 
(114). Moreover, in Marilyn TCR transgenic mice expressing 
HY-specific CD4+ T cells, increased conversion of effector 
CD4+ T cells into CD25+ Foxp3+ pTregs was observed (114). 
Whether these effects were due to a direct Ag presentation of 
endogenously expressed HY to CD4+ T cells by gp38+ stromal 
cells, i.e., LECs and FRCs in the LN, remains to be determined. 
Indeed, as stated by the authors, they cannot rule out that other, 
non-DC, hematopoietic cell types could contribute to the presen-
tation of HY Ags, due to undesired transduction and subsequent 
direct Ag presentation and/or Ag transfer to stromal cells (110, 
114). Despite a lack of demonstration of direct Ag presentation 
by gp38+ stromal cells and the lack of distinction between the 
contribution of the different stromal cell subtypes in this model, 
these data are in accordance with the results of Baptista et al., as 
mentioned above (113).
Molecular Pathways involved in  
LeC-Mediated Peripheral T Cell Tolerance
The molecular pathways involved in the clonal deletion of 
CD8+ T cells by LNSCs, and in particular by LECs, are not fully 
elucidated. Using the iFABP-tOVA transgenic mouse model 
described above, in which tOVA is expressed as a self-Ag in 
the intestinal epithelium, it was shown that the induction of 
CD8+ T cell tolerance requires PD-1:PD-L1 interaction, as the 
disruption of this pathway leads to severe intestinal enteric 
autoimmune disorder (115). More specifically, in a model of 
adoptive transfer of Tyr-specific TCR transgenic CD8+ T cells 
(FH T cells) into Tyr-expressing bone marrow chimeric mice, 
in which either radiosensitive hematopoietic or radioresistant 
non-hematopoietic cells lacked PD-L1 expression, FH T cells 
were deleted only when PD-L1 was expressed by the non-
hematopoietic LN compartment (116). Moreover, among the 
LNSC subsets, LECs were the ones expressing the highest level of 
PD-L1, with medullary sinuses LECs being the highest express-
ers. In addition, LECs do not express costimulatory molecules 
at their surface. The administration of agonistic anti-4-1BB 
antibodies prevented the deletion of FH CD8+ T cells. The lack 
of costimulation through 4-1BB by LECs would lead to PD-1 
upregulation by FH T cells, as Tyr presentation by LECs led to 
a higher expression of PD-1 by FH T cells, an effect that was 
suppressed upon agonistic anti-4-1BB antibody administration. 
This would, in turn, prevent CD25 upregulation, which is neces-
sary for CD8+ T cells survival. Indeed, CD25 expression on FH 
T cells was upregulated only in the presence of agonistic anti-4-
1BB or blocking anti-PD-L1 antibodies after Tyr presentation by 
LECs (116). Hence, in this model, LECs are responsible for the 
presentation of the endogenously expressed Tyr, which, together 
with a combination of a lack of costimulation and a provision of 
co-inhibitory signal, leads to Tyr-specific CD8+ T cell deletion 
(116). The high expression of PD-L1 in LECs is likely regulated 
by lymphotoxin β receptor (Ltβr), as the treatment of mice with 
anti-Ltβr antibodies led to decreased PD-L1 expression in LECs 
(104). Using μMT−/−, CD3ε−/−, and Rag1−/− mice, it was further 
shown that B cells are required for the expression of the adhe-
sion molecule MadCAM-1 at the surface of LECs in the medulla, 
itself necessary for the expression of PD-L1. On the contrary, 
T cells seemed to suppress PD-L1 expression in LECs through 
mechanisms that have not been deciphered yet (104). Finally, 
it was suggested that the expression of MHC-II on LECs would 
be involved in the induction of CD8+ T cells tolerance to endog-
enously expressed self-Ag in LECs by engaging the inhibitory 
molecule LAG-3. Indeed, after adoptive transfer of β-gal-specific 
TCR transgenic CD8+ T cells (Bg1 cells) into Prox-1xβgal mice, 
in which β-gal is selectively expressed by LECs, the proliferation 
of Bg1 cells was increased following administration of blocking 
anti-LAG-3 antibodies, which was acting in synergy with anti-
PD-L1 blocking antibodies (45).
We previously showed that high PD-L1 expression by LECs 
correlate with their unique ability, compared to other LNSC 
subsets, to induce CD4+ T cell apoptosis after presentation of 
DC-acquired peptide–MHC-II complexes (110). Although 
the molecular mechanisms accounting for the induction of 
tolerance to MHC-II-restricted self-Ag endogenously expressed 
and directly presented by LECs to CD4+ T cells have not been 
elucidated so far, they are thus likely to involve PD-L1 expression 
by LECs, as in the case of CD8+ T cells.
Ag Acquisition and Presentation by  
LeCs to T Cells
The lymphatic system, by controlling Ag availability, consti-
tutes one of the first checkpoints for immune responses (100). 
It is not surprising then that LECs, which have early access to 
any given Ag, display different mechanisms for Ag uptake and 
processing (Figure  2). Indeed, recent work revealed that Ag 
trafficking can be observed at more levels than the classical con-
cept of LECs as lymph carriers. Complex interactions between 
FiGURe 2 | Pathways of Ag acquisition and presentation by LeCs. Several pathways of antigen (Ag) acquisition and loading coexist in lymphatic endothelial 
cells (LECs). Interactions with dendritic cells (DCs) underlie complex mechanisms of Ag transfer in both directions. On one hand, LECs act as Ag reservoirs for DCs 
which can uptake LEC-derived Ag. The mechanisms accounting for this phenomenon remain however unclear. On the other hand, LECs acquire peptide–MHC-II 
complexes from DCs in a cell–cell contact dependent manner (DC-derived Ag is depicted in yellow). DC-derived exosomes might also be implicated. Peripheral 
tissue-restricted Ags (PTA) (in pink) expressed by LEC can be loaded into MHC-I molecules. Intracellular pathways of degradation of such PTAs have however been 
not investigated. Moreover, whether PTA can be incorporated in MHC-II compartments is still a matter of debate. Alternatively, LECs possess the ability to uptake 
exogenous lymph-borne and tumor-derived Ag that can be incorporated in MHC-I pathway in a TAP-1-dependent manner. Related references are indicated in 
numbers.
8
Humbert et al. Role of LECs in Peripheral T Cell Responses
Frontiers in Immunology | www.frontiersin.org January 2017 | Volume 7 | Article 684
LECs and DCs (45, 110, 117) depict an exciting picture of Ag 
bidirectional exchange that ultimately may serve to modulate 
the overall magnitude of the immune response (Figure 2).
Uptake of exogenous Ag
It has been extensively demonstrated in several mouse and 
human models that LECs exhibit an active endocytotic capac-
ity (38, 118). They are able to uptake exogenous molecules and, 
depending on their location, process Ag for cross-presentation 
and cross-priming of Ag-specific CD8+ T cells (63, 64) (Figure 2). 
Interestingly, Ag-loaded primary LN LECs were shown to be 
capable of cross-priming Ag-specific CD8+ T cells in a TAP1-
dependent manner (64). As described above for endogenous 
PTA presentation, Ag-loaded LECs induced T cell apoptosis, the 
lack of expression of costimulatory molecules being the most 
extended explanation. LECs neither express nor upregulate the 
costimulatory molecules CD40, CD80, and CD86 following TLR 
engagement or in presence of IFN-γ or TNF-α (110, 116). While 
LECs upregulate the immunostimulatory molecules HVEM, 
CD48, and MHC-II under such conditions (116), they also 
upregulate PD-L1 (102, 110, 119). Pointing at the same direction, 
Ag cross-presentation by LSECs induces tolerized CD8+ T cells 
in the liver. In this context, PD-L1 expression was also relevant 
for such outcome (120). Interestingly, in the absence of inflam-
mation, surviving LSEC-educated T cells had an Ag-experienced 
central memory-like phenotype in SLOs (121). Furthermore, 
LSEC-primed memory T cells could be reactivated in vitro and 
in vivo in an Ag-specific manner, and they could contribute to a 
viral challenge (121).
The direct contribution of Ag presentation by LECs to 
CD4+ viral immunity is still a matter of debate. As mentioned 
above, LECs serve as Ag reservoir during viral infections (117) 
(Figure 2). Nonetheless, genetic ablation of MHC-II in radiore-
sistant stromal cells in LNs resulted in longer maintenance of 
Ag-specific CD4+ T cells (122). Specific impact of LN LECs and 
mechanisms accounting for such effects should be yet clarified.
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Cellular Ag Transfer
The hallmark of professional APCs is the constitutive cell surface 
presence of MHC-II and their ability for Ag processing and 
presentation (123). Constitutive MHC-II expression is restricted 
to a small number of cells of the immune system. Nonetheless, 
there are many different cell types from both hematopoietic and 
non-hematopoietic origins that can indeed express MHC-II and 
interact with CD4+ T cells in the periphery (100, 124, 125).
As mentioned above, LECs constitute such non-professional 
APC cell types that express MHC-II in an IFN-γ-dependent man-
ner. Indeed, MHC-II expression in LN LECs has been reported at 
both transcriptional and protein expression levels (102, 110, 111). 
By using transgenic mouse models lacking the different CIITA 
promoters, we have previously demonstrated that steady-state 
levels of MHC-II molecules on the surface of LECs and other 
stromal subsets in LNs reflect a combination of IFN-γ-inducible 
basal activity and acquired peptide:MHC-II complexes from 
DCs (110). The acquired MHC-II molecules were loaded with 
DC-derived Ags, licensing LECs to induce anergy and increased 
cell death Ag-specific CD4+ T cells (Figures  1B and 2). Lack 
of measurable productive T cell responses has been one of the 
major difficulties preventing the clarification of the impact of 
Ag presentation by LECs on CD4+ T cell outcome. As for CD8+  
T cell responses, the absence of costimulatory signals, such as 
CD80 or CD86 and the constitutive expression of PD-L1 by LECs, 
preclude the possibility of functional effector CD4+ T cell prim-
ing. In this regard, it has been shown that human LN-derived 
LECs fail to induce allogeneic CD4+ T cell proliferation even after 
IFN-γ stimulation (119). In these particular in vitro settings, LECs 
were unable to induce proliferation of either naïve or memory 
CD4+ T cells.
Membrane exchange between cells is not uncommon in immu-
nology (126). Peptide:MHC-I and MHC-II complexes have been 
shown to be transferred between DC and tumor cells (127) or 
infected cells (128), as well as between DCs (129). Ag transfer can 
occur as peptide exchange on cell surfaces. Peptide epitopes can 
bind directly on cell surface or early endosomal MHC molecules 
(130), where both MHC-I and MHC-II are receptive for lymph-
borne peptide binding. This might be particularly relevant in the 
context of self-tolerance, since recent analyses showed that the 
human lymph peptidome contains predominantly self-peptides, 
including products derived from extracellular processing of 
proteins (131). Exosomes were also implicated in the transfer of 
peptide:MHC-II complexes from DCs to LNSCs (110), and they 
cannot be excluded to contribute to alternative Ag trafficking 
(Figure 2).
Antigen transfer between LECs and DCs is, however, not 
restricted to one direction. Indeed, the transfer of PTAs specifi-
cally expressed in LECs to hematopoietic cells has been described 
(45) (Figure 2). Neither membrane-bound nor cytoplasmic PTAs 
were directly presented by LECs to prime Ag-specific CD4+ T cell 
responses. As mentioned above, this was attributed to the lower 
expression of H2-M in LECs compared to professional APCs, 
which is required for peptide binding into the MHC-II groove. 
Instead, peptides derived from PTAs expressed by LECs were 
found to be loaded onto MHC-II in DCs (45). While the exchange 
mechanism is still open to examination, it was reported not to be 
dependent on recognition of apoptotic cells or DC phagocytosis. 
These complementary bidirectional observations highlight the 
close relationship and communication between professional 
APCs and LECs to enable MHC-II presentation.
CONCLUDiNG ReMARKS
Increasing evidence suggest that lymphatics are much more than 
simple pipes that drain tissue-derived fluids containing proteins, 
particles, and cells. Through the expression of different surface 
molecules and the production of soluble factors, LECs indeed 
modulate immune responses in many ways, including the active 
regulation of cellular migration, interactions, and functions. 
Recent studies have highlighted a possible role for LECs as 
direct instructors of T cell immunity. Indeed, the discovery that 
LNSCs, including LECs, ectopically express tissue-derived Ags, 
a feature thought to be restricted to mTECs and thymic central 
T cell tolerance, has pushed forward LECs to potentially func-
tion as Ag-presenting cells. Accordingly, the selective expression 
of model Ags in LECs leads to an Ag-specific recognition by 
T cells, which, after an early step of activation and proliferation, 
are either inactivated or deleted. Therefore, the presentation of 
endogenously expressed Ags by LECs seems to contribute to 
peripheral T cell tolerance. Studies have also suggested that LECs 
acquire exogenous Ags by distinct pathways, including direct 
uptake, or cell-membrane transfer, and present them to induce 
T cell dysfunction. The molecular mechanisms contributing 
to LEC ability to inactivate T cells are still not fully elucidated. 
However, a consensus candidate, PD-L1, the ligand for program-
cell death 1 receptor expressed by T cells, emerged from several 
recent studies to be highly expressed by LECs, and important to 
mediate T cell tolerance. Although pioneering studies suggest 
that Ag-presenting LNSCs are sufficient to maintain peripheral 
T cell tolerance, the specific contribution of LECs remains to be 
addressed. Likewise, substantial differences among LECs from 
distinct anatomical locations entail different functions. Specific 
roles of local LECs should be carefully dissected in order to fully 
understand how they differentially impact T cell responses. In 
addition, most studies so far have been performed in steady state, 
and the contribution of Ag presentation by LECs under different 
pathological conditions in shaping of peripheral T cell responses 
remains to be determined. In addition, future studies will assess 
how current therapies for cancer or autoimmune diseases aiming 
at modulating immune cell functions, specifically alter the ability 
of LECs to impact T cell responses.
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